MRD: A Shared Compass for Patients, Clinicians, and Regulators

A Shared Compass for Patients, Clinicians, and Regulators

MILAN — The landscape of hematologic malignancies is shifting rapidly, in part due to the evolving significance of measurable (formerly “minimal”) residual disease (MRD). Once confined to the realm of research, MRD is emerging as a critical tool for clinical and regulatory decision-making. In conditions such as acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), […] The post A Shared Compass for Patients, Clinicians, and Regulators…

MRD: A Shared Compass for Patients, Clinicians, and Regulators

The debate continues over the potential of measurable residual disease to transform research and clinical care in hematology.